UC Berkeley’s Groundbreaking Study on Psilocybin

The UC Berkeley Center for the Science of Psychedelics has embarked on an unprecedented study to explore why psilocybin, a psychoactive compound found in certain mushrooms, alters visual perception in humans.

This investigation represents the university’s first human trials involving a Schedule I substance, classified by the federal government as having no accepted medical use.

Psilocybin, commonly known as “shrooms” or “magic mushrooms,” can significantly distort users’ sense of time, mood, and reality, often causing hallucinations.

Read more

F.D.A. Panel Votes Against MDMA-Assisted Therapy for PTSD

The Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee voted overwhelmingly to reject MDMA-assisted therapy in the treatment of post traumatic stress disorder, or PTSD.

The FDA will issue its final decision on the matter in mid-August but in the majority of cases, the federal agency’s decisions align with the vote of the independent panelists on advisory committees.

Read more